何鎰明
Project ID: C23-M001-00477
Report No.: AA-23-01050_ONC
Date Reported: Mar 07, 2023

ACT Onco® + Report

PATIENT		
Identifier: 何鎰明		Patient ID: 49088973
Date of Birth: Aug 22, 1959		Gender: Male
Diagnosis: Ampulla of vater adenocarcinoma		
ORDERING PHYSICIAN		
Name: 姜乃榕醫師		Tel: 886-228712121
Facility: 臺北榮總		
Address: 臺北市北投區石牌路二段 201 號		
SPECIMEN		
Specimen ID: S11171876G	Collection site: Ampulla of vater	Type: FFPE tissue
Date received: Feb 21, 2023	Lab ID: AA-23-01050	D/ID: NA

ABOUT ACTOnco®+

The test is a next-generation sequencing (NGS)-based assay developed for efficient and comprehensive genomic profiling of cancers. This test interrogates coding regions of 440 genes associated with cancer treatment, prognosis and diagnosis. Genetic mutations detected by this test include small-scale mutations like single nucleotide variants (SNVs), small insertions and deletions (InDels) (≤ 15 nucleotides) and large-scale genomic alterations like copy number alterations (CNAs). The test also includes an RNA test, detecting fusion transcripts of 13 genes.

SUMMARY FOR ACTIONABLE VARIANTS

VARIANTS/BIOMARKERS WITH EVIDENCE OF CLINICAL SIGNIFICANCE

Genomic Alterations/Biomarkers	Probable Effects in Patient's Cancer Type		Probable Sensitive in Other Cancer Types
	Sensitive	Resistant	
Not detected			

VARIANTS/BIOMARKERS WITH POTENTIAL CLINICAL SIGNIFICANCE

Genomic Alterations/Biomarkers	Possibly Sensitive	Possibly Resistant
BRAF G469A	Dabrafenib, Trametinib	Cetuximab, Panitumumab, Vemurafenib
GNAS R201H	Trametinib	-

Note:

- The above summary tables present genomic variants and biomarkers based on the three-tiered approach proposed by US FDA for reporting tumor profiling NGS testing. "Variants/biomarkers with evidence of clinical significance" refers to mutations that are widely recognized as standard-of-care biomarkers (FDA level 2/AMP tier 1). "Variants/biomarkers with potential clinical significance" refers to mutations that are not included in the standard of care but are informational for clinicians, which are commonly biomarkers used as inclusion criterial for clinical trials (FDA level 3/AMP tier 2).
- The therapeutic agents and possible effects to a given drug are based on mapping the variants/biomarkers with ACT Genomics clinical knowledge database. The mapping results only provide information for reference, but not medical recommendation.
- Please refer to corresponding sections for more detailed information about genomic alteration and clinical relevance listed above.

ACT Onco® + Report

TESTING RESULTS

VARIANT(S) WITH CLINICAL RELEVANCE

- Single Nucleotide and Small InDel Variants

Gene	Amino Acid Change	Allele Frequency
BRAF	G469A	14.1%
GNAS	R201H	26.8%
TP53	C135Y	19.3%

- Copy Number Alterations

Chromosome	Gene	Variation	Copy Number
Not detected			

- Fusions

Fusion Gene & Exon	Transcript ID
No fusion gene detected in this sample	

- Immune Checkpoint Inhibitor (ICI) Related Biomarkers

Biomarker	Results
Tumor Mutational Burden (TMB)	< 1 muts/Mb
Microsatellite Instability (MSI)	Microsatellite stable (MSS)

Note:
- Variant(s) enlisted in the SNV table may currently exhibit no relevance to treatment response prediction. Please refer to INTERPRETATION for more biological information and/or potential clinical impacts of the variants.
- Loss of heterozygosity (LOH) information was used to infer tumor cellularity. Copy number alteration in the tumor was determined based on 30% tumor purity.
- TMB was calculated by using the sequenced regions of ACTOnco®+ to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The threshold for high mutation load is set at ≥ 7.5 mutations per megabase. TMB, microsatellite status and gene copy number deletion cannot be determined if calculated tumor purity is < 30%.

ACT Onco® + Report

THERAPEUTIC IMPLICATIONS

TARGETED THERAPIES

Genomic Alterations	Therapies	Effect
Level 4		
BRAF G469A	Dabrafenib, Trametinib	**sensitive**
GNAS R201H	Trametinib	**sensitive**
BRAF G469A	Cetuximab, Panitumumab, Vemurafenib	**resistant**

Therapies associated with benefit or lack of benefit are based on biomarkers detected in this tumor and published evidence in professional guidelines or peer-reviewed journals.

Level	Description
1	FDA-recognized biomarkers predictive of response or resistance to FDA approved drugs in this indication
2	Standard care biomarkers (recommended by the NCCN guideline) predictive of response or resistance to FDA approved drugs in this indication
3A	Biomarkers predictive of response or resistance to therapies approved by the FDA or NCCN guideline in a different cancer type
3B	Biomarkers that serve as inclusion criteria for clinical trials (minimal supportive data required)
4	Biomarkers that show plausible therapeutic significance based on small studies, few case reports, or preclinical studies

ACT Onco® + Report

IMMUNE CHECKPOINT INHIBITORS (ICIs)

No genomic alterations detected to confer sensitivity or lack of benefit to immune checkpoint therapies.

- Other Biomarkers with Potential Clinical Effects for ICIs

Genomic Alterations	Potential Clinical Effects
Not detected	

Note: Tumor non-genomic factors, such as patient germline genetics, PDL1 expression, tumor microenvironment, epigenetic alterations or other factors not provided by this test may affect ICI response.

CHEMOTHERAPIES

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to chemotherapies.

HORMONAL THERAPIES

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to hormonal therapies.

OTHERS

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to other therapies.

Note:
Therapeutic implications provided in the test are based solely on the panel of 440 genes sequenced. Therefore, alterations in genes not covered in this panel, epigenetic and post-transcriptional and post-translational factors may also determine a patient's response to therapies. In addition, several other patient-associated clinical factors, including but not limited to, prior lines of therapies received, dosage and combinations with other therapeutic agents, patient's cancer types, sub-types, and/or stages, may also determine the patient's clinical response to therapies.

VARIANT INTERPRETATION

BRAF G469A

Biological Impact

BRAF is a serine/threonine kinase that belongs to the RAF family. The protein plays an essential role in the regulation of mitogen-activated protein kinase (MAPK) cascade, which affects a range of cellular response including cell division, differentiation, and secretion[1][2]. Mutations in the BRAF gene, most commonly the V600 residue, are the most frequently identified oncogenic mutations in melanomas, and have been identified in several types of cancers including non-Hodgkin lymphoma, thyroid cancers, non-small cell lung carcinoma, hairy cell leukemia, glioma, gastrointestinal stromal tumor, and colorectal cancers (CRCs)[3][4]. Of note, in the vast majority of cases, BRAF mutations are non-overlapping with other oncogenic mutations (e.g., NRAS mutations, KIT mutations, etc.) found in melanoma. V600E has been determined to be an activating mutation, which results in enhanced BRAF kinase activity and constitutive activation of downstream MEK/ERK signaling cascade[5][6].

BRAF G469A mutation occurred at the protein kinase domain of the BRAF protein and has been shown to increase BRAF kinase activity and promote downstream signaling in the MAPK pathway[7][3].

Therapeutic and prognostic relevance

A retrospective study indicated that similar to other BRAF kinase domain mutation subtypes, BRAF non-V600E mutations (G469A included) also predicts a less benefit of anti-EGFR monoclonal antibody treatment in patients with heavily-pretreated colorectal cancer[8].

In a Phase II trial (NCI-MATCH), trametinib resulted in stable disease in a patient with lung adenocarcinoma harboring BRAF G469A, who had remained on therapy for 20 months without progression[9].

The preclinical study demonstrated that compared to trametinib or dabrafenib single treatment, a combined trametinib and dabrafenib treatment enhances and prolongs the ERK inhibition and antiproliferative effect in BRAF G469A-expressing NSCLC cell line[10]. A case report demonstrated a patient with NSCLC harboring BRAF G469A had a durable response to dabrafenib and trametinib for 6 months[11].

Meanwhile, the mutation BRAF G469A in metastatic melanoma cell lines has shown weak responsiveness to vemurafenib[12], and vemurafenib treatment did not show efficacy in patients with advanced solid tumors harboring BRAF G469A (NCT02304809, NCT02091141)[13][14].

In a preclinical study, selumetinib treatment inhibited proliferation of NSCLC cells harboring EGFR exon 19 deletion and BRAF G469A and resulted in increased cell death and both decreased cell migration and Mapk pathway signaling compared to osimertinib treatment only in vitro[15].

The NCCN guidelines for central nervous system cancers recommended selumetinib for pilocytic astrocytoma patients with BRAF fusion or BRAF V600E activating mutation. BRAF activating mutations have been determined as an inclusion criterion for the trials evaluating selumetinib efficacies in cancers (NCT01089101, NCT00888134, NCT00866177, and NCT00936221).

GNAS R201H

Biological Impact

GNAS encodes the alpha subunit of the stimulator G protein (Gs-alpha), a guanine-nucleotide binding protein (G protein) involved in the hormonal regulation of adenylate cyclase[16]. The common mutations of GNAS have been identified in tumors, including R201C, R201H, and Q227R, resulting in constitutive activation of Gs-alpha and its effector adenylate cyclase, leading to increased cAMP accumulation, and constitutive cAMP signaling, associated with excessive

proliferation and tumor development[17][18][16]. GNAS activation may affect downstream MAPK and Wnt signaling pathway, suggesting activating mutation of GNAS can modify cell growth and may be oncogenic[18].

GNAS R201H is a missense mutation at codon 201, resulting in a change of amino acid from an arginine to a histidine. This variant has been shown to be an activating mutation in vitro[17][19].

Therapeutic and prognostic relevance

Low expression of GNAS has been reported to associate with both poor overall survival and PSA progression-free survival in prostate cancer[20].

A case report showed that a patient with a mucinous appendiceal adenocarcinoma and pseudomyxoma peritonei (PMP) harboring GNAS R201H mutation experienced clinical benefit from trametinib[21]. Moreover, a follicular thyroid carcinoma patient with concomitant NRAS Q61K and GNAS R201H mutations exhibited good response to radioactive iodine[22].

TP53 C135Y

Biological Impact

TP53 encodes the p53 protein, a crucial tumor suppressor that orchestrates essential cellular processes including cell cycle arrest, senescence and apoptosis[23]. TP53 is a proto-typical haploinsufficient gene, such that loss of a single copy of TP53 can result in tumor formation[24].

C135Y is a missense mutation located in the DNA-binding domain of the p53 protein (UniProtKB), conferring a loss-of-function to the p53 protein as demonstrated by loss of binding to the Drosha complex and inability to induce downstream miRs[25].

Therapeutic and prognostic relevance

Despite having a high mutation rate in cancers, there are currently no approved targeted therapies for TP53 mutations. A phase II trial demonstrated that Wee1 inhibitor (AZD1775) in combination with carboplatin was well tolerated and showed promising anti-tumor activity in TP53-mutated ovarian cancer refractory or resistant (< 3 months) to standard first-line therapy (NCT01164995)[26].

In a retrospective study (n=19), advanced sarcoma patients with TP53 loss-of-function mutations displayed improved progression-free survival (208 days versus 136 days) relative to patients with wild-type TP53 when treated with pazopanib[27]. Results from another Phase I trial of advanced solid tumors (n=78) demonstrated that TP53 hotspot mutations are associated with better clinical response to the combination of pazopanib and vorinostat[28].

Advanced solid tumor and colorectal cancer patients harboring a TP53 mutation have been shown to be more sensitive to bevacizumab when compared with patients harboring wild-type TP53[29][30][31]. In a pilot trial (n=21), TP53-negative breast cancer patients demonstrated increased survival following treatment with bevacizumab in combination with chemotherapy agents, Adriamycin (doxorubicin) and Taxotere (docetaxel)[32]. TP53 mutations were correlated with poor survival of advanced breast cancer patients receiving tamoxifen or primary chemotherapy[33][34]. In a retrospective study of non-small cell lung cancer (NSCLC), TP53 mutations were associated with high expression of VEGF-A, the primary target of bevacizumab, offering a mechanistic explanation for why patients exhibit improved outcomes after bevacizumab treatment when their tumors harbor mutant TP53 versus wild-type TP53[35].

ACT Onco® + Report

US FDA-APPROVED DRUG(S)

Dabrafenib (TAFINLAR)

Dabrafenib is a reversible ATP-competitive kinase inhibitor of the enzyme B-Raf, which plays a role in the regulation of cell growth via the ERK signaling cascade. Dabrafenib is developed and marketed by GlaxoSmithKline under the trade name TAFINLAR.

- FDA Approval Summary of Dabrafenib (TAFINLAR)

BRF117019, NCI-MATCH, CTMT212X2101 NCT02034110, NCT02465060, NCT02124772	**Cancer** (Approved on 2022/06/22)
	BRAF V600E
	Dabrafenib + trametinib [ORR(adult patients)(%): 41.0, ORR(pediatric patients)(%): 25.0]
BRF117019[36] NCT02034110	**Thyroid gland anaplastic carcinoma** (Approved on 2018/05/04)
	BRAF V600E
	Dabrafenib + trametinib [ORR(%): 61.0]
BRF113928[37] NCT01336634	**Non-small cell lung cancer** (Approved on 2017/06/22)
	BRAF V600E
	Dabrafenib + trametinib vs. Dabrafenib [ORR(%): 64.0 vs. 52.0]
COMBI-d[38] NCT01584648	**Melanoma** (Approved on 2014/01/10)
	BRAF V600E
	Dabrafenib + trametinib vs. Dabrafenib + placebo [PFS(M): 9.8 vs. 8.8]
COMBI-v[39] NCT01597908	**Melanoma** (Approved on 2014/01/10)
	BRAF V600E
	Dabrafenib + trametinib vs. Vemurafenib [OS(M): 11.4 vs. 7.3]
BREAK-3[40] NCT01227889	**Melanoma** (Approved on 2013/05/29)
	BRAF V600E
	Dabrafenib vs. Dacarbazine [PFS(M): 5.1 vs. 2.7]

Trametinib (MEKINIST)

Trametinib is an anti-cancer inhibitor which targets MEK1 and MEK2. Trametinib is developed and marketed by GlaxoSmithKline (GSK) under the trade name MEKINIST.

- FDA Approval Summary of Trametinib (MEKINIST)

BRF117019, NCI-MATCH, CTMT212X2101 NCT02034110, NCT02465060, NCT02124772	**Cancer** (Approved on 2022/06/22)
	BRAF V600E
	Dabrafenib + trametinib [ORR(adult patients)(%): 41.0, ORR(pediatric patients)(%): 25.0]
BRF117019[36] NCT02034110	**Anaplastic thyroid cancer** (Approved on 2018/05/04)
	BRAF V600E
	Dabrafenib + trametinib [ORR(%): 61.0]
BRF113928[41] NCT01336634	**Non-small cell lung cancer** (Approved on 2017/06/22)
	BRAF V600E
	Trametinib + dabrafenib vs. Dabrafenib [ORR(%): 63.0 vs. 27.0, DOR(M): 12.6 vs. 9.9]

ACT Onco® + Report

COMBI-d[42] NCT01584648	**Melanoma** (Approved on 2014/01/10)
	BRAF V600E/K
	Trametinib + dabrafenib vs. Dabrafenib + placebo [PFS(M): 9.3 vs. 8.8]
METRIC[43] NCT01245062	**Melanoma** (Approved on 2013/05/29)
	BRAF V600E/K
	Trametinib vs. Dacarbazine or paclitaxel [PFS(M): 4.8 vs. 1.5]

D=day; W=week; M=month

ACT Onco® + Report

ONGOING CLINICAL TRIALS

Trials were searched by applying filters: study status, patient's diagnosis, intervention, location and/or biomarker(s). Please visit https://clinicaltrials.gov to search and view for a complete list of open available and updated matched trials.

No trial has been found.

ACT Onco® + Report

SUPPLEMENTARY INFORMATION OF TESTING RESULTS

DETAILED INFORMATION OF VARIANTS WITH CLINICAL RELEVANCE

- Single Nucleotide and Small InDel Variants

Gene	Amino Acid Change	Exon	cDNA Change	Accession Number	COSMIC ID	Allele Frequency	Coverage
BRAF	G469A	11	c.1406G>C	NM_004333	COSM460	14.1%	1563
GNAS	R201H	8	c.602G>A	NM_000516	COSM27895	26.8%	325
TP53	C135Y	5	c.404G>A	NM_000546	COSM10801	19.3%	683

- Copy Number Alterations

Observed copy number (CN) for each evaluated position is shown on the y-axis. Regions referred to as amplification or deletion are shown in color. Regions without significant changes are represented in gray.



ACT Onco® + Report

OTHER DETECTED VARIANTS

Gene	Amino Acid Change	Exon	cDNA Change	Accession Number	COSMIC ID	Allele Frequency	Coverage
ADH1C	R364H	8	c.1091G>A	NM_000669	-	47.7%	176
AXIN2	G601A	7	c.1802G>C	NM_004655	-	60.4%	338
BIRC2	C85F	2	c.254G>T	NM_001166	-	63.1%	1985
CDK12	P650L	3	c.1949C>T	NM_016507	-	44.6%	625
DPYD	R332W	10	c.994C>T	NM_000110	COSM8602859	8.8%	944
FGFR4	R203H	6	c.608G>A	NM_213647	COSM6913139	52.9%	554
KMT2A	S947fs	3	c.2839dup	NM_001197104	-	26.1%	207
KMT2C	Q2462H	37	c.7386G>T	NM_170606	-	50.8%	2358
KMT2D	R4721C	44	c.14161C>T	NM_003482	COSM2006723	52.0%	900
MUC16	R1863S	1	c.5589G>T	NM_024690	-	52.8%	1014
POLD1	D644E	16	c.1932C>G	NM_001256849	-	49.2%	606

Note:

- This table enlists variants detected by the panel other than those with clinical relevance (reported in Testing Result section). The clinical impact of a genetic variant is determined according to ACT Genomics in-house clinical knowledge database. A negative result does not necessarily indicate absence of biological effect on the tumor. Some variants listed here may possibly have preclinical data or may show potential clinical relevance in the future.

TEST DETAILS

SPECIMEN RECEIVED AND PATHOLOGY REVIEW



- Collection date: Dec 06, 2022
- Facility retrieved: 臺北榮總
- H&E-stained section No.: S11171876G
- Collection site: Ampulla of vater
- Examined by: Dr. Yeh-Han Wang
    1. The percentage of viable tumor cells in total cells in the whole slide (%): 10%
    2. The percentage of viable tumor cells in total cells in the encircled areas in the whole slide (%): 30%
    3. The percentage of necrotic cells (including necrotic tumor cells) in total cells in the whole slide (%): 0%
    4. The percentage of necrotic cells (including necrotic tumor cells) in total cells in the encircled areas in the whole slide (%): 0%
    5. Additional comment: NA
- Manual macrodissection: Performed on the highlighted region
- The outline highlights the area of malignant neoplasm annotated by a pathologist.

RUN QC

- Panel: ACTOnco®+

DNA test

- Mean Depth: 807x
- Target Base Coverage at 100x: 94%

RNA test

- Average unique RNA Start Sites per control GSP2: 169

LIMITATIONS

1. This test does not provide information of variant causality and does not detect variants in non-coding regions that could affect gene expression. This report does not report polymorphisms and we do not classify whether a mutation is germline or somatic. Variants identified by this assay were not subject to validation by Sanger or other technologies.
2. The possibility cannot be excluded that certain pathogenic variants detected by other sequencing tools may not be reported in the test because of technical limitation of bioinformatics algorithm or the NGS sequencing platform, e.g. low coverage.
3. This test has been designed to detect fusions in 13 genes sequenced. Therefore, fusion in genes not covered by this test would not be reported. For novel fusions detected in this test, Sanger sequencing confirmation is recommended if residue specimen is available.

ACT Onco® + Report

NEXT-GENERATION SEQUENCING (NGS) METHODS

DNA test

Extracted genomic DNA was amplified using primers targeting coding exons of analyzed genes and subjected to library construction. Barcoded libraries were subsequently conjugated with sequencing beads by emulsion PCR and enriched using Ion Chef system. Sequencing was performed according to Ion Proton or Ion S5 sequencer protocol (Thermo Fisher Scientific).

Raw reads generated by the sequencer were mapped to the hg19 reference genome using the Ion Torrent Suite. Coverage depth was calculated using Torrent Coverage Analysis plug-in. Single nucleotide variants (SNVs) and short insertions/deletions (InDels) were identified using the Torrent Variant Caller plug-in. VEP (Variant Effect Predictor) was used to annotate every variant using databases from Clinvar, COSMIC and Genome Aggregation database. Variants with coverage ≥ 20, allele frequency ≥ 5% and actionable variants with allele frequency ≥ 2% were retained. This test provides uniform coverage of the targeted regions, enabling target base coverage at 100x ≥ 85% with a mean coverage ≥ 500x.

Variants reported in Genome Aggregation database with > 1% minor allele frequency (MAF) were considered as polymorphisms. ACT Genomics in-house database was used to determine technical errors. Clinically actionable and biologically significant variants were determined based on the published medical literature.

The copy number alterations (CNAs) were predicted as described below:
Amplicons with read counts in the lowest 5th percentile of all detectable amplicons and amplicons with a coefficient of variation ≥ 0.3 were removed. The remaining amplicons were normalized to correct the pool design bias. ONCOCNV (an established method for calculating copy number aberrations in amplicon sequencing data by Boeva et al., 2014) was applied for the normalization of total amplicon number, amplicon GC content, amplicon length, and technology-related biases, followed by segmenting the sample with a gene-aware model. The method was used as well for establishing the baseline of copy number variations.

Tumor mutational burden (TMB) was calculated by using the sequenced regions of ACTOnco®+ to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The TMB calculation predicted somatic variants and applied a machine learning model with a cancer hotspot correction. TMB may be reported as “TMB-High”, “TMB-Low” or “Cannot Be Determined”. TMB-High corresponds to ≥ 7.5 mutations per megabase (Muts/Mb); TMB-Low corresponds to < 7.5 Muts/Mb. TMB is reported as “Cannot Be Determined” if the tumor purity of the sample is < 30%.

Classification of microsatellite instability (MSI) status is determined by a machine learning prediction algorithm. The change of a number of repeats of different lengths from a pooled microsatellite stable (MSS) baseline in > 400 genomic loci are used as the features for the algorithm. The final output of the results is either microsatellite Stable (MSS) or microsatellite instability high (MSI-H).

RNA test

Extracted RNA was reverse-transcribed and subjected to library construction. Sequencing was performed according to Ion Proton or Ion S5 sequencer protocol (Thermo Fisher Scientific). To ensure sequencing quality for fusion variant analysis, the average unique RNA Start Sites (SS) per control Gene Specific Primer 2 (GSP 2) should be ≥ 10.

The fusion analysis pipeline aligned sequenced reads to the human reference genome, identified regions that map to noncontiguous regions of the genome, applied filters to exclude probable false-positive events and, annotated previously characterized fusion events according to Quiver Gene Fusion Database, a curated database owned and maintained by ArcherDX. In general, samples with detectable fusions need to meet the following criteria: (1) Number of unique start sites (SS) for the GSP2 ≥ 3; (2) Number of supporting reads spanning the fusion junction ≥ 5; (3) Percentage of supporting reads spanning the fusion junction ≥ 10%; (4) Fusions annotated in Quiver Gene Fusion Database.

ACT Onco® + Report

DATABASE USED

- Reference genome: Human genome sequence hg19
- COSMIC v.92
- Genome Aggregation database r2.1.1
- ClinVar (version 20210404)
- ACT Genomics in-house database
- Quiver Gene Fusion Database version 5.1.18

Variant Analysis:
醫檢師陳韻仔 博士
Yun-Yu Chen Ph.D.
檢字第 015647 號

Yun Yu Chen

Sign Off
解剖病理專科醫師王業翰
Yeh-Han Wang M.D.
病解字第 000545 號

GENE LIST

SNV & CNV

ABCB1*	ABCC2*	ABCG2*	ABL1	ABL2	ADAMTS1	ADAMTS13	ADAMTS15	ADAMTS16	ADAMTS18	ADAMTS6	ADAMTS9
ADAMTSL1	ADGRA2	ADH1C*	AKT1	AKT2	AKT3	ALDH1A1*	ALK	AMER1	APC	AR	ARAF
ARID1A	ARID1B	ARID2	ASXL1	ATM	ATR	ATRX	AURKA	AURKB	AXIN1	AXIN2	AXL
B2M	BAP1	BARD1	BCL10	BCL2*	BCL2L1	BCL2L2*	BCL6	BCL9	BCOR	BIRC2	BIRC3
BLM	BMPR1A	BRAF	BRCA1	BRCA2	BRD4	BRIP1	BTG1	BTG2*	BTK	BUB1B	CALR
CANX	CARD11	CASP8	CBFB	CBL	CCNA1	CCNA	CCNB1	CCNB2	CCNB3	CCND1	CCND2
CCND3	CCNE1	CCNE2	CCNH	CD19	CD274	CD58	CD70*	CD79A	CD79B	CDC73	CDH1
CDK1	CDK12	CDK2	CDK4	CDK5	CDK6	CDK7	CDK8	CDK9	CDKN1A	CDKN1B	CDKN2A
CDKN2B	CDKN2C	CEBPA*	CHEK1	CHEK2	CIC	CREBBP	CRKL	CRLF2	CSF1R	CTCF	CTLA4
CTNNA1	CTNNB1	CUL3	CYLD	CYP1A1*	CYP2B6*	CYP2C19*	CYP2C8*	CYP2D6	CYP2E1*	CYP3A4*	CYP3A5*
DAXX	DCUN1D1	DDR2	DICER1	DNMT3A	DOT1L	DPYD	DTX1	E2F3	EGFR	EP300	EPCAM
EPHA2	EPHA3	EPHA5	EPHA7	EPHB1	ERBB2	ERBB3	ERBB4	ERCC1	ERCC2	ERCC3	ERCC4
ERCC5	ERG	ESR1	ESR2	ETV1	ETV4	EZH2	FAM46C	FANCA	FANCC	FANCD2	FANCE
FANCF	FANCG	FANCL	FAS	FAT1	FBXW7	FCGR2B	FGF1*	FGF10	FGF14	FGF19*	FGF23
FGF3	FGF4*	FGF6	FGFR1	FGFR2	FGFR3	FGFR4	FH	FLCN	FLT1	FLT3	FLT4
FOXL2*	FOXP1	FRG1	FUBP1	GATA1	GATA2	GATA3	GNA11	GNA13	GNAQ	GNAS	GREM1
GRIN2A	GSK3B	GSTP1*	GSTT1*	HGF	HIF1A	HIST1H1C*	HIST1H1E*	HNF1A	HR	HRAS*	HSP90AA1
HSP90AB1	HSPA4	HSPA5	IDH1	IDH2	IFNL3*	IGF1	IGF1R	IGF2	IKBKB	IKBKE	IKZF1
IL6	IL7R	INPP4B	INSR	IRF4	IRS1	IRS2*	JAK1	JAK2	JAK3	JUN*	KAT6A
KDM5A	KDM5C	KDM6A	KDR	KEAP1	KIT	KMT2A	KMT2C	KMT2D	KRAS	LCK	LIG1
LIG3	LMO1	LRP1B	LYN	MALT1	MAP2K1	MAP2K2	MAP2K4	MAP3K1	MAP3K7	MAPK1	MAPK3
MAX	MCL1	MDM2	MDM4	MED12	MEF2B	MEN1	MET	MITF	MLH1	MPL	MRE11
MSH2	MSH6	MTHFR*	MTOR	MUC16	MUC4	MUC6	MUTYH	MYC	MYCL	MYCN	MYD88
NAT2*	NBN	NEFH	NF1	NF2	NFE2L2	NFKB1	NFKBIA	NKX2-1*	NOTCH1	NOTCH2	NOTCH3
NOTCH4	NPM1	NQO1*	NRAS	NSD1	NTRK1	NTRK2	NTRK3	PAK3	PALB2	PARP1	PAX5
PAX8	PBRM1	PDCD1	PDCD1LG2	PDGFRA	PDGFRB	PDIA3	PGF	PHOX2B*	PIK3C2B	PIK3C2G	PIK3C3
PIK3CA	PIK3CB	PIK3CD	PIK3CG	PIK3R1	PIK3R2	PIK3R3	PIM1	PMS1	PMS2	POLB	POLD1
POLE	PPARG	PPP2R1A	PRDM1	PRKAR1A	PRKCA	PRKCB	PRKCG	PRKCI	PRKCQ	PRKDC	PRKN
PSMB8	PSMB9	PSME1	PSME2	PSME3	PTCH1	PTEN	PTGS2	PTPN11	PTPRD	PTPRT	RAC1
RAD50	RAD51	RAD51B	RAD51C	RAD51D	RAD52	RAD54L	RAF1	RARA	RB1	RBM10	RECQL4
REL	RET	RHOA	RICTOR	RNF43	ROS1	RPPH1	RPTOR	RUNX1	RUNX1T1	RXRA	SDHA
SDHB	SDHC	SDHD	SERPINB3	SERPINB4	SETD2	SF3B1	SGK1	SH2D1A*	SLC19A1*	SLC22A2*	SLCO1B1*
SLCO1B3*	SMAD2	SMAD3	SMAD4	SMARCA4	SMARCB1	SMO	SOCS1*	SOX2*	SOX9	SPEN	SPOP
SRC	STAG2	STAT3	STK11	SUFU	SYK	SYNE1	TAF1	TAP1	TAP2	TAPBP	TBX3
TEK	TERT	TET1	TET2	TGFBR2	TMSB4X*	TNF	TNFAIP3	TNFRSF14	TNFSF11	TOP1	TP53
TPMT*	TSC1	TSC2	TSHR	TYMS	U2AF1	UBE2A*	UBE2K	UBR5	UGT1A1*	USH2A	VDR*
VEGFA	VEGFB	VHL	WT1	XIAP	XPO1	XRCC2	ZNF217				

*Analysis of copy number alterations NOT available.

FUSION

ALK	BRAF	EGFR	FGFR1	FGFR2	FGFR3	MET	NRG1	NTRK1	NTRK2	NTRK3	RET	ROS1

ACT Onco® + Report

APPENDIX

POSSIBLE THERAPEUTIC IMPLICATIONS FOR HETEROZYGOUS DELETION

Not Applicable.

SIGNALING PATHWAYS AND MOLECULAR-TARGETED AGENTS



1: Dabrafenib; 2: Trametinib

ACT Onco® + Report

DISCLAIMER

法律聲明

本檢驗報告僅提供專業醫療參考，結果需經專業醫師解釋及判讀。基因突變資訊非必具備藥物或治療有效性指標，反之亦然。本檢驗報告提供之用藥指引不聲明或保證其臨床有效性，反之亦然。本基因檢測方法係由本公司研究開發，已經過有效性測試。
本檢驗報告非經本公司許可，不得私自變造、塗改，或以任何方式作為廣告及其他宣傳之用途。
本公司於提供檢驗報告後，即已完成本次契約義務，後續之報告解釋、判讀及用藥、治療，應自行尋求相關專業醫師協助，若需將報告移件其他醫師，本人應取得該醫師同意並填寫移件申請書，主動告知行動基因，行動基因僅能配合該醫師意願與時間提供醫師解說。

醫療決策需由醫師決定

任何治療與用藥需經由醫師在考慮病患所有健康狀況相關資訊包含健檢、其他檢測報告和病患意願後，依照該地區醫療照護標準由醫師獨立判斷。醫師不應僅依據單一報告結果(例如本檢測或本報告書內容)做決策。

基因突變與用藥資訊並非依照有效性排序

本報告中列出之生物標記變異與藥物資訊並非依照潛在治療有效性排序。

證據等級

藥物潛在臨床效益(或缺乏潛在臨床效益)的實證證據是依據至少一篇臨床療效個案報告或臨床前試驗做為評估。本公司盡力提供適時及準確之資料，但由於醫學科技之發展日新月異，本公司不就本報告提供的資料是否為準確、適宜或最新作保證。

責任

本檢驗報告僅提供專業醫療參考，本公司及其員工不對任何由使用本報告之內容引起的直接、間接、特殊、連帶或衍生的損失或損害承擔責任。

ACT Onco® + Report

REFERENCE

1. PMID: 15520807; 2004, Nat Rev Mol Cell Biol;5(11):875-85
The RAF proteins take centre stage.

2. PMID: 24737949; 2014, J Carcinog;13():1
BRAF and beyond: Tailoring strategies for the individual melanoma patient.

3. PMID: 12068308; 2002, Nature;417(6892):949-54
Mutations of the BRAF gene in human cancer.

4. PMID: 24071849; 2013, Nat Genet;45(10):1113-20
The Cancer Genome Atlas Pan-Cancer analysis project.

5. PMID: 20179705; 2010, Nature;464(7287):427-30
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.

6. PMID: 21388974; 2011, Mol Cancer Ther;10(3):385-94
BRAFV600E: implications for carcinogenesis and molecular therapy.

7. PMID: 19010912; 2008, Cancer Res;68(22):9375-83
Genetic predictors of MEK dependence in non-small cell lung cancer.

8. PMID: 28972961; 2017, Br J Cancer;117(10):1450-1458
Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.

9. PMID: 31924734; 2020, Clin Cancer Res;26(8):1812-1819
Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131).

10. PMID: 28947956; 2017, Oncotarget;8(36):60094-60108
Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.

11. PMID: 32981611; 2020, J Thorac Oncol;15(10):e174-e176
Durable Response to Dabrafenib Combined With Trametinib in a Patient With NSCLC Harboring a BRAF G469A Mutation.

12. PMID: 26070258; 2015, Cancer Chemother Pharmacol;76(2):433-8
Metastatic melanoma cells with BRAF G469A mutation: nab-paclitaxel better than vemurafenib?

13. PMID: 29320312; 2018, J Clin Oncol;36(6):536-542
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

14. PMID: 31959346; 2020, Ann Oncol;31(2):289-294
Vemurafenib in non-small-cell lung cancer patients with BRAF^{V600} and BRAF^{nonV600} mutations.

15. PMID: 31502118; 2019, Target Oncol;14(5):619-626
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion.

16. PMID: 20887824; 2011, Bone;48(2):312-20
Potent constitutive cyclic AMP-generating activity of XLαs implicates this imprinted GNAS product in the pathogenesis of McCune-Albright syndrome and fibrous dysplasia of bone.

17. PMID: 2549426; 1989, Nature;340(6236):692-6
GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours.

18. PMID: 20531296; 2010, Oncogene;29(32):4567-75
The activating mutation R201C in GNAS promotes intestinal tumourigenesis in Apc(Min/+) mice through activation of Wnt and ERK1/2 MAPK pathways.

19. PMID: 24498230; 2014, PLoS One;9(1):e87966
GNAS mutations identify a set of right-sided, RAS mutant, villous colon cancers.

20. PMID: 24741584; 2014, J Immunol Res;2014():301376
Gαs protein expression is an independent predictor of recurrence in prostate cancer.

21. PMID: 28868010; 2017, Case Rep Oncol;10(2):548-552
Clinical Benefit from Trametinib in a Patient with Appendiceal Adenocarcinoma with a GNAS R201H Mutation.

22. PMID: 26788326; 2016, Endocrinol Diabetes Metab Case Rep;2016():150067
Follicular thyroid carcinoma with NRAS Q61K and GNAS R201H mutations that had a good (131)I treatment response.

23. PMID: 24739573; 2014, Nat Rev Cancer;14(5):359-70
Unravelling mechanisms of p53-mediated tumour suppression.

24. PMID: 21125671; 2011, J Pathol;223(2):137-46
Haplo-insufficiency: a driving force in cancer.

25. PMID: 19626115; 2009, Nature;460(7254):529-33
Modulation of microRNA processing by p53.

26. PMID: 27998224; 2016, J Clin Oncol;34(36):4354-4361
Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.

27. PMID: 26646755; 2016, Ann Oncol;27(3):539-43
TP53 mutational status is predictive of pazopanib response in advanced sarcomas.

28. PMID: 25669829; 2015, Ann Oncol;26(5):1012-8
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.

29. PMID: 27466356; 2016, Mol Cancer Ther;15(10):2475-2485
TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics.

30. PMID: 23670029; 2013, Oncotarget;4(5):705-14
P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy.

31. PMID: 17145525; 2006, Semin Oncol;33(5 Suppl 10):S8-14
Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.

32. PMID: 21399868; 2011, Int J Oncol;38(5):1445-52
p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer.

33. PMID: 20549698; 2011, Int J Cancer;128(8):1813-21
p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines.

34. PMID: 10786679; 2000, Cancer Res;60(8):2155-62
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.

35. PMID: 25672981; 2015, Cancer Res;75(7):1187-90
VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy.

36. PMID: 29072975; 2018, J Clin Oncol;36(1):7-13
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.

ACT Onco® + Report

37. PMID: 27283860; 2016, Lancet Oncol;17(7):984-993
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.

38. PMID: 26037941; 2015, Lancet;386(9992):444-51
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.

39. PMID: 25399551; 2015, N Engl J Med;372(1):30-9
Improved overall survival in melanoma with combined dabrafenib and trametinib.

40. PMID: 22735384; 2012, Lancet;380(9839):358-65
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

41. PMID: 27080216; 2016, Lancet Oncol;17(5):642-50
Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.

42. PMID: 25265492; 2014, N Engl J Med;371(20):1877-88
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

43. PMID: 22663011; 2012, N Engl J Med;367(2):107-14
Improved survival with MEK inhibition in BRAF-mutated melanoma.